Company Culture

None of the above.

 

Currently working with s dynamic company in Ophthalmology and really enjoying the challenges and daily success of a dominant glaucoma device company. I’m sure you don’t have to think too long as to identify the company I speak of. Ok, I’m done wasting time here. Good luck to you.

 

Sounds like option C?

 

Omg, in what World is alimera a drug company , without a development Departement. And without an Vision.
And by the way this thing isn't for glaucoma therapie

 

I was referring to the commany I work for now, not Alimera. Gla...Glau...Glauk....come on you can do it!

 

OK couscous I thought you were done wasting time here. Addicted, much?

 

On February 28, 2019, Calvin W. Roberts, M.D. notified the Board of Directors (the “Board”) of Alimera Sciences, Inc. (the “Company”) that he will resign as a director, effective at the Company’s 2019 Annual Meeting of Stockholders.

 

Meaningful factors that could cause actual results to differ include:

a slowdown or reduction in our sales in due to a reduction in end user demand, unanticipated competition, regulatory issues, or other unexpected circumstances;

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13251214&RcvdDate=2/25/2019&CoName=ALIMERA%20SCIENCES%20INC&FormType=10-K&View=html

 

The company has negative cash flow and is in debt over 377 million dollars! I’m not a betting man, but.....

 

Wow...that’s terrible.

 

We commenced operations in June 2003. Since our inception we have incurred significant losses. As of December 31, 2018, we had accumulated a deficit of $ 377.1 million . We expect to incur substantial losses through the continued commercialization of ILUVIEN as we:
•
continue the commercialization of ILUVIEN in the U.S. and EEA, where we sell direct, and in other countries in the EEA and the Middle East, where we sell through our distributors;
•
continue to seek regulatory approval of ILUVIEN for other indications and in other jurisdictions;
•
evaluate the use of ILUVIEN for the treatment of other diseases; and
•
advance the clinical development of any future products or product candidates either currently in our pipeline, or that we may license or acquire in the future.
As of December 31, 2018, we had approximately $ 13.0 million in cash and cash equivalents.

 

Only 13 million in cash at the end of 2018! That means we probably only have 9-10 million once this quarter ends!

 

Zombie Company.....

 

when your #1 rep resigns you know things are going south

 

Which territory?

 

The truth is out there

 

byE, MH

 

it's for family bereavement, you f*cking piece of shit.

 

The death of his career